IN8bio Reports Third Quarter Financial Results
IN8bio (NASDAQ: INAB) has released its financial results for the third quarter, highlighting a significant reduction in net loss per share. The company reported a net loss of $0.24 per share, a substantial improvement compared to the $0.85 loss recorded during the same period last year. Despite the improved bottom line, operating expenses saw an upward trend. Research and development costs rose by 23.5% year-over-year to $2.6 million, while general and administrative expenses increased by 13.9% to $2.1 million. Total operating expenses for the quarter reached $4.7 million, representing a 19% increase compared to the previous year.
Tickers: $INAB
Topics: net loss operating expenses R&D expenses